Targeting the $5 BILLION Soft Tissue Repair Market
Chitogenx is in the regulatory lead for regenerative products + signs MOU with major Medical Institute
Philippe Deschamps is an experienced Healthcare Executive who has served as CEO of three companies over the last 20 years. The depth of his expertise stems from his 36 years in the Life Sciences industry spent at Bristol Myers Squibb, GSW Worldwide, a leading healthcare commercialization company, and Helius Medical Technologies, a NeuroTech company. As co-founder and CEO of Helius Medical Technologies, Mr. Deschamps took the company public on both the TSXV and NASDAQ stock exchanges and raised $100M to commercialize their Neurotech product PoNS. The product gained approval in both Canada and the US.
At GSW, Mr. Deschamps was President and CEO and was responsible for the GSW expansion into a Worldwide operation to support the globalization of Pharma. Under his watch, revenues grew from $30M from 2 US offices in 2002 to $160M in annual revenue from 16 countries in 2011. During his tenure, he stayed heavily involved with the company's top clients and developed innovative partnerships to increase performance and save money.
Before joining GSW Worldwide, Mr. Deschamps served as director of neuroscience marketing at Bristol- Myers Squibb (BMS) in Princeton, N.J., where he oversaw the company's neuroscience products including BUSPAR SERZONE and STADOL NS. He also held several marketing positions in the neuroscience, pain and metabolic therapeutic areas throughout his career. Mr. Deschamps has a BSc. from the University of Ottawa in Canada.
Mr. LeDuc has cumulated 32 years of senior executive, CEO, COO experience with private and Fortune 500 medical device and bio-pharma companies. He has spent 22 years in the musculoskeletal market, having occupied senior positions with Genzyme, Biomatrix, Serono and BioSyntech. He has raised more than $50 million in public & private financings after taking BioSyntech public on the TSX-V exchange as its CEO in 2004. During his 5year tenure as BioSyntech CEO, he has worked closely with Ecole Polytechnique who is an active partner in the development of Ortho-RTi's proprietary platform, and was directly involved in the clinical and regulatory development of the BST-CarGel product which was later acquired by Orthopaedic giant, Smith & Nephew.
Luc Mainville, MBA
Senior VP, Chief Financial Officer
Mr. Mainville has an accomplished history of financial and operational leadership successes within the life science industry. In an executive management career that spans more than 20 years, he has led or been integrally involved in four go-public transactions, completed more than 20 public financings, and managed more than 50 licensing, merger and acquisition, and sale transactions. Mr. Mainville also serves as Senior Vice President and CFO for Valeo Pharma. His earlier experience includes senior management and financial roles with various life science companies, including Acerus Pharma, Cardiome Pharma, Neopharm Labs and LAB Research Inc. Prior to launching his career in the life science industry, Mr. Mainville was a Partner at KPMG LLP. Mr. Mainville has also served as Vice-Chairman of BIOTECanada and holds an MBA from McGill University.
VP Clinical and Medical Affairs
Mukesh Ahuja, MBBS, MSc is a highly qualified, medical executive with fourteen years of US experience as a clinical expert in Orthopedics, managing dozens of orthopedic clinical studies and partnering with surgeons to advance novel research approaches. He has validated expertise in leading and supporting clinical and medical affairs teams within biotechnology companies, medical centers, and clinical research organizations, and has partnered with leading orthopedics companies in exploring novel technologies. Dr. Ahuja has practical knowledge of experimental and clinical research needs to support the development, commercialization and marketing of medical products and technologies. He has a long history of collaboration with physicians, surgeons, scientists/researchers, engineers, sales and marketing executives and other key advisors to identify new markets, and areas of growth and sustainability. Dr. Ahuja worked at Orthofix Medical, Inc. where he was appointed to develop the clinical strategy for the motion preservation program of spine business franchise. He was also responsible to initiate and lead an IDE trial for a two-level cervical disc replacement device. Prior to Orthofix, Dr. Ahuja was the Director of Medical and Clinical Affairs for Medacta USA, Inc.
Chairman of the Board
Mr. Atkin has over 30 years of experience in life sciences as an entrepreneur, start-up executive, leader and manager in the pharmaceutical and biotechnology industries, and in advancing early stage research towards commercialization based on satisfying unmet medical needs.
Mr. Atkin is President of Syzent Partners Ltd. ("Syzent"), a consulting firm in life sciences based in Montreal, QC. Prior to founding Syzent in 2008, Mr. Atkin was Executive Chair and subsequently CEO of Ulysses Pharmaceuticals, focused on overcoming antibiotic resistance. He was previously the founding CEO of Aegera Therapeutics, an apoptosis control company formed by the merger of McGill spinout Exogen Neurosciences with Apoptogen, where he raised $33m in two financing rounds, and advanced two novel first-in-class drugs to the clinic. At the helm of Aegera, Mr. Atkin advanced multiple technology and product partnerships with major pharmaceutical companies, generating several million dollars in revenues.
Mr. Saviuk has an extensive background in finance and venture capital investing including a number of successful health science companies. He co founded Valeo Pharma in 2003 and has served as its President and CEO since its inception and has overseen its transformation from its early years as an in licensor of established brands to a fast growing full service Canadian pharmaceutical company.
Brent Norton, MD
Dr. Norton is a leader in the Life Science industry with operational and Director experience across several successful enterprises which achieved significant multiples for investors. Dr. Norton founded PreMD, completing IPO's and listings on both TSX and AMEX. Operationally, he has built R&D and commercial operations, led transactions with AstraZeneca, Atherogenics, Eli Lilly, L'Oreal, Parke Davis/Pfizer, etc., and taken products through the FDA to global out-licensing with Johnson & Johnson. He is a founding Director of Novadaq Technologies (TSX:NDQ, NASDAQ:NVDQ), one of Canada's most valuable medical companies. Dr. Norton has been an active member of several BOD's, public and private, in both Canada and the US. He is a Venture Partner at Lumira Capital, a member of the Research Committee for CAMH, an Advisory BOD member for the Ivey International Centre for Health Innovation, and a Past-President and Director of the Osler Bluff Ski Club and Director of Alpine Ontario.
Dr. Buschmann is Chair of Bioengineering at George Mason University in Fairfax VA, USA. From 1994 to 2017 he was a Professor at Polytechnique Montréal. He has a Ph.D. in Medical Engineering and Medical Physics from MIT and Harvard University, with postdoctoral training in cartilage repair and histology completed at the University of Bern in Switzerland. Since 1994 he conducted a multidisciplinary research program at Polytechnique Montréal that focuses on the use of biomaterials to repair meniscus, rotator cuff and cartilage and to deliver mRNA and small interfering RNA using nanovectors.
Tom Wright is an accomplished and respected business and community leader, with extensive experience in the North American, Australian and New Zealand sports/entertainment industry that spans more than 35 years. Prior to the UFC, he was Managing Director of Level 5 Strategic Brand Advisors, one of Canada's foremost business and brand strategy firms. Before serving four years as Commissioner for the Canadian Football League from 2002 through 2006, he was the President and CEO for Salomon North American, President adidas Canada LTD and President of Spalding Canada LTD. He has also been significantly involved with Special Olympics Canada as a volunteer for more than 30 years and served as the organization's National Board Chairman.
Tom holds a Bachelor of Physical and Health Education degree from the University of Toronto as well as his MBA from The Schulich School of Business at York University. Tom recently concluded the Directors Education Program at U of T's Rotman School of Management, a program focused on board governance offered through the Institute of Corporate Directors.
Mr. Pierre Laurin is a senior executive with more than 35 years of experience in the pharmaceutical and biotechnology industry. He founded Prometic Life Sciences Inc. in 1994 and took the company public on the Toronto Stock Exchange in 1998. He served as President and Chief Executive Officer of the Corporation since its inception until December 2018 during which period he raised close to $1 billion in equity, debt financing and multinational funding. Mr. Laurin's corporate development achievements include the successful closing of multiple licensing agreements and partnering agreements with multinationals, including two strategic agreements with the American Red Cross, which led to commercial applications and blood derived therapeutics. Mr. Laurin's prior experience also includes positions with various pharmaceutical companies, including Nordic Laboratories (now Sanofi) where he played a pivotal role in the development and commercial success of Cardizem® in Canada and in the UK.
He is currently a board member of Innodem Neurosciences Inc., Innovon Pharmaceuticals Inc. and Invhealth Capital Inc. Mr. Laurin holds a Bachelor degree in Pharmacy and an MSc degree in Pharmaceutical Sciences from the University of Montreal.
Caroline Hoemann is a Professor at Polytechnique Montréal since October 2005 as well as a member of the Biomedical Science and Technologies Research Group (GRSTB). Dr. Hoemann has a M.Sc. in Applied Biology and a Ph.D. in Toxicology from MIT. She is a member of the Ordre des Ingénieurs du Québec since 2010, and was awarded Junior II, Senior, and National career fellowships from the Fonds de la Recherche Santé du Quebec (FRQ-S) for her research in biomaterial devices for articular cartilage repair.